Compare HLT & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLT | BDX |
|---|---|---|
| Founded | 1919 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Hotels/Resorts | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 67.5B | 51.5B |
| IPO Year | 2013 | 1994 |
| Metric | HLT | BDX |
|---|---|---|
| Price | $291.68 | $159.56 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 15 | 11 |
| Target Price | ★ $308.27 | $189.60 |
| AVG Volume (30 Days) | 1.8M | ★ 2.4M |
| Earning Date | 05-13-2026 | 01-01-0001 |
| Dividend Yield | 0.20% | ★ 2.63% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.12 | 1.34 |
| Revenue | $12,039,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $9.59 | N/A |
| Revenue Next Year | $8.38 | $2.53 |
| P/E Ratio | ★ $48.06 | $118.97 |
| Revenue Growth | 7.74 | ★ 8.24 |
| 52 Week Low | $196.04 | $158.20 |
| 52 Week High | $333.86 | $231.82 |
| Indicator | HLT | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 35.86 | 23.13 |
| Support Level | $286.40 | N/A |
| Resistance Level | $306.28 | $195.22 |
| Average True Range (ATR) | 7.72 | 4.18 |
| MACD | -2.55 | -1.05 |
| Stochastic Oscillator | 7.33 | 3.91 |
Hilton Worldwide Holdings operates 1.35 million rooms across its 25 brands, serving the premium economy through luxury segments. Hampton and Hilton are the two largest brands, representing 27% and 18%, respectively, of the company's total rooms, as of Dec. 31, 2025. Recent brands launched over the past few years include Home2, Curio, Canopy, Spark, Tru, Tempo, LivSmart, and Outset. Additionally, there is a partnership with Small Luxury Hotels of the World and acquisitions of NoMad and Graduate Hotels. Managed and franchised hotels represent the vast majority of adjusted EBITDA, predominantly from the Americas.
Becton Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures prefilled devices, diagnostic instruments, and reagents, as well as flow cytometry and cell-imaging systems. On a 2025 sales basis, following the spinoff, BD Medical Essentials represented 34% of revenue, the Interventional segment 28%, Connected Care 25%, and Biopharma 13%. International revenue accounts for 43% of the company's business.